Sage Bionetworks and Celgene have initiated a mobile health research study 'Journey PRO' addressing quality of life for patients with chronic anaemia caused by myelodysplastic syndromes (MDS) myelofibrosis and beta-thalassemia.

The study will use a smartphone-based app and wearable technologies to collect and analyse patient-reported data to understand disease burden on these patients and for enhanced therapeutic developments.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

During the study period, Apple ResearchKit framework and various surveys will be employed to collect patient data, including Digital Artifacts’ BrainBaseline cognitive testing software for neurological self-assessments, and the iPhone HealthKit and fitness tracking wearables for health data collection.

The firms intend to use the results from these quantitative assessments to develop a tool for evaluating the efficacy of new treatments in minimising the impact of the diseases on patients.

Data obtained through the study will be immediately given to the patients to aid them in managing their health.

See Also:

"Journey PRO will provide direct and immediate information back to research participants to help them manage their health."

Sage Bionetworks president Lara Mangravite said: “Understanding the impact of disease on daily living is important to patients as well as researchers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“For this reason, Journey PRO will provide direct and immediate information back to research participants to help them manage their health.”

Designed with input from chronic anaemia community members, the Journey PRO app will allow participants to track, download and share health data such as transfusions and lab values.

The study will include chronic anaemia patients aged 18 years and above, individuals diagnosed with myelodysplastic syndromes (MDS) myelofibrosis and beta-thalassemia, and is also open to non-diagnosed people to facilitate comparison in quality of life measures.